Day 3 Recap: AAD 2026

To stay informed with the latest conference insights, follow us on LinkedIn, Facebook, X, and Instagram, and subscribe to receive our eNewsletters.

Brepocitinib Results May End Decades of Steroid-Dependent Dermatomyositis Management

The FDA has granted Priority Review to brepocitinib's NDA for dermatomyositis, with a Q3 2026 PDUFA date that could make it the first drug specifically approved for this indication.

Practical Geriatric Dermatology Pearls Shared at AAD Annual Meeting

Daniel C. Butler, MD, discusses adherence challenges, medication risks, and practical strategies to optimize dermatologic care in older adults.

AAD 2026: Extended Study Highlights Dual Role of Subcutaneous and Intravenous Spesolimab for GPP Management

LEO Pharma shared 2 posters with data from the ongoing EFFISAYIL ON program, supporting long-term use of spesolimab for generalized pustular psoriasis.

Late-Breaking Data: Tape Strip Profiling Reveals Divergent Molecular Pathways in Skin Aging

At AAD 2026, Helen He, MD, highlights how minimally invasive molecular profiling distinguishes photoexposed and photoprotected aging trajectories.

Lebrikizumab Delivers Near-Complete Skin Clearance Without Topical Corticosteroids at 4 Years

Eight in ten ADlong patients achieved clinical response without steroid rescue, strengthening the case for lebrikizumab as a standalone, long-term management option.

AAD 2026: Intratumoral PH762 Shows Early Efficacy in Cutaneous SCC With No Immune-Related Adverse Events

During the late-breaking research session at the 2026 AAD Annual Meeting 2026, Mary Spellman, MD, shared successful news about intratumoral PH762 for cutaneous carcinomas.

Precision and Progress: Key Updates in Skin Cancer Prevention, Diagnosis, and Management

New sunscreen filters, AI tools, and immunotherapies are reshaping skin cancer prevention and treatment, improving precision and long-term survival.

Tralokinumab Delivers Sustained 12-Month Relief in Skin of Color and Difficult-to-Treat AD

LEO Pharma presented 3 AAD posters on the efficacy of tralokinumab in various AD subgroups across the 12-month TRACE program.

AAD 2026: 52-Week Icotrokinra Data Show High Rates of Skin Clearance and Consistent Safety in Plaque Psoriasis

Liza O'Dowd, MD, shared insights on the latest data on icotrokinra at the AAD Annual Meeting.

Executive Insights: Extended-Release Oral Minoxidil Shows Optimized Pharmacokinetics and Potential to Enhance Hair Growth

At AAD 2026, Christopher Bunick, MD, PhD, and Reid Waldman, MD, discuss investigational VDPHL01, extended-release oral minoxidil, for the treatment of women and men with pattern hair loss.